These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 15362927)

  • 1. Pharmacoeconomic implications of new therapies in sepsis.
    Wood KA; Angus DC
    Pharmacoeconomics; 2004; 22(14):895-906. PubMed ID: 15362927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.
    Frampton JE; Foster RH
    Pharmacoeconomics; 2004; 22(7):445-76. PubMed ID: 15137883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic aspects of severe sepsis: a review of intensive care unit costs, cost of illness and cost effectiveness of therapy.
    Burchardi H; Schneider H
    Pharmacoeconomics; 2004; 22(12):793-813. PubMed ID: 15294012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simplified pharmacoeconomics of critical care and severe sepsis.
    Ernst FR; Levy H; Qualy RL
    J Intensive Care Med; 2007; 22(5):283-93. PubMed ID: 17895486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures.
    Betancourt M; McKinnon PS; Massanari RM; Kanji S; Bach D; Devlin JW
    Pharmacoeconomics; 2003; 21(18):1331-40. PubMed ID: 14750900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The costs and cost-effectiveness of an integrated sepsis treatment protocol.
    Talmor D; Greenberg D; Howell MD; Lisbon A; Novack V; Shapiro N
    Crit Care Med; 2008 Apr; 36(4):1168-74. PubMed ID: 18379243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economics of sepsis.
    Chalupka AN; Talmor D
    Crit Care Clin; 2012 Jan; 28(1):57-76, vi. PubMed ID: 22123099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.
    De Backer D
    Drug Saf; 2007; 30(11):995-1010. PubMed ID: 17973539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drotrecogin alfa (recombinant human activated protein C) in severe sepsis--a New Zealand viewpoint.
    Liang J; Streat S; Torrance J; Sleigh J; Freebairn R; Ramsay M
    N Z Med J; 2003 Sep; 116(1181):U586. PubMed ID: 14581969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
    Davies A; Ridley S; Hutton J; Chinn C; Barber B; Angus DC
    Anaesthesia; 2005 Feb; 60(2):155-62. PubMed ID: 15644013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drotrecogin alfa (activated; Xigris): an effective and cost-efficient treatment for severe sepsis.
    Doig CJ; Zygun DA; Delaney A; Manns BJ
    Expert Rev Pharmacoecon Outcomes Res; 2004 Feb; 4(1):15-26. PubMed ID: 19807332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies.
    Krauth C; Jalilvand N; Welte T; Busse R
    Pharmacoeconomics; 2003; 21(14):1001-24. PubMed ID: 13129414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economic burden of sepsis in Austria.
    Schmid A; Schneider H
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):1023-4; author reply 1024. PubMed ID: 12635473
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.
    Kalil AC; LaRosa SP
    Lancet Infect Dis; 2012 Sep; 12(9):678-86. PubMed ID: 22809883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Economic and Humanistic Burden of Severe Sepsis.
    Tiru B; DiNino EK; Orenstein A; Mailloux PT; Pesaturo A; Gupta A; McGee WT
    Pharmacoeconomics; 2015 Sep; 33(9):925-37. PubMed ID: 25935211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis.
    Costa V; Brophy JM
    BMC Anesthesiol; 2007 Jun; 7():5. PubMed ID: 17592639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An economic evaluation of activated protein C treatment for severe sepsis.
    Manns BJ; Lee H; Doig CJ; Johnson D; Donaldson C
    N Engl J Med; 2002 Sep; 347(13):993-1000. PubMed ID: 12324556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).
    Micek ST; Isakow W; Shannon W; Kollef MH
    Pharmacotherapy; 2005 Jan; 25(1):26-34. PubMed ID: 15767217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.